Insulator dysfunction and oncogene activation in IDH mutant gliomas. - Wikidata - awgldk - TriplyDB

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

http://www.wikidata.org/entity/Q34506441

about

Brainstem Glioma in Adults The second decade of 3C technologies: detailed insights into nuclear organization Brain tumor modeling using the CRISPR/Cas9 system: state of the art and view to the future Understanding Spatial Genome Organization: Methods and Insights IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives Transcriptional Dynamics at Brain Enhancers: from Functional Specialization to Neurodegeneration Oncometabolites: Unconventional triggers of oncogenic signalling cascades The Future is The Past: Methylation QTLs in Schizophrenia Emerging concepts of epigenetic dysregulation in hematological malignancies The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation Epigenetics in Cancer: A Hematological Perspective Epigenetic determinants of metastasis CTCF: making the right connections Overcoming therapeutic resistance in glioblastoma: the way forward Isocitrate Dehydrogenase Mutation Leads to Alteration in 3-Dimensional DNA Structure and Oncogene Activation in Gliomas.Enhancers and chromatin structures: regulatory hubs in gene expression and diseases.The Cohesin Release Factor WAPL Restricts Chromatin Loop Extension Super-Enhancers and Broad H3K4me3 Domains Form Complex Gene Regulatory Circuits Involving Chromatin Interactions.CTCF and cohesin regulate chromatin loop stability with distinct dynamics.Cancer metabolism as a central driving force of glioma pathogenesis YY1 and CTCF orchestrate a 3D chromatin looping switch during early neural lineage commitment Non-Coding Loss-of-Function Variation in Human Genomes.Insulated Neighborhoods: Structural and Functional Units of Mammalian Gene Control.Mutational Biases Drive Elevated Rates of Substitution at Regulatory Sites across Cancer Types Perspectives: using polymer modeling to understand the formation and function of nuclear compartments.Functional interrogation of non-coding DNA through CRISPR genome editing.A Tox21 Approach to Altered Epigenetic Landscapes: Assessing Epigenetic Toxicity Pathways Leading to Altered Gene Expression and Oncogenic Transformation In Vitro Characteristics of gliomas in patients with somatic IDH mosaicism.Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.TAD disruption as oncogenic driver.The three-dimensional cancer genome.A genetic polymorphism affects the risk and prognosis of renal cell carcinoma: association with follistatin-like protein 1 expression.Chromatin and Epigenetics at the Forefront: Finding Clues among Peaks Tet2 and Tet3 cooperate with B-lineage transcription factors to regulate DNA modification and chromatin accessibility.The Shh Topological Domain Facilitates the Action of Remote Enhancers by Reducing the Effects of Genomic Distances iRegNet3D: three-dimensional integrated regulatory network for the genomic analysis of coding and non-coding disease mutations.IGFBP2 expression predicts IDH-mutant glioma patient survival.Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.Crossed wires: 3D genome misfolding in human disease.CCCTC-Binding Factor Translates Interleukin 2- and α-Ketoglutarate-Sensitive Metabolic Changes in T Cells into Context-Dependent Gene Programs.

P2860

Q26739232-4D391FD3-5CA4-4931-A2E5-8E51837284F4 Q26747370-CDCD8984-521C-4614-8A79-14FE017FEF62 Q26753206-E91B226C-D876-4C00-B128-3023D03C635D Q26766143-D8EB7F69-346E-4B83-BADE-0B718B36B765 Q28066926-8C77AC20-FBBD-47C2-89B4-1BC165238C24 Q28067751-B795A2C6-0EE4-4FE3-B6A0-2FFD5E65E31D Q28069594-4DE6A533-465D-4AFC-BEDE-2E77B01C4999 Q28073441-F7394723-028C-4B9F-891D-CFCA8D6012FA Q28074522-21C09499-979A-4CC1-838A-9E525CBE5E2F Q28075374-EB0E0378-1728-4AF0-8F40-2CE63EAFB8B4 Q28077082-35DA88D4-C59C-4FD7-A155-30E6E1707D41 Q28079377-39338AA1-8014-4341-B473-2F8C5603AA53 Q28079447-1147A101-D76A-4D83-A01A-7E28F99C01B4 Q29248396-517E56BA-DC78-4CD2-BCB0-1EA832F68BF2 Q30276789-BA6A1E13-6D86-40FC-B0C7-CDD7D44461A4 Q33613467-4B962ABA-B46B-42DC-B00A-84DA9A64CD58 Q33649701-54951218-F1FA-432E-A43D-E8C27F1E85EA Q33708447-57922A4A-345E-49BD-A9B0-191AA84EA97B Q33732376-1BF96BAA-3F3C-4982-98E4-B4F8FF32964A Q33847616-2077F32E-F8E9-4755-9E33-05B50CE41467 Q33865154-B6ED23B0-80E8-408D-A08D-91345CABC600 Q33878483-152E562D-18A7-4633-A79A-F4A2704E112A Q34545070-009D8D77-4562-46AF-A0AC-B494D9B6BB2D Q36095027-CF4C56C9-86C9-4D76-90DF-9644B5521BB5 Q36250466-8308C979-C208-43F6-AF81-ACDA46DE3B2F Q36306820-ED1B34BE-A785-4F76-A174-F3C32E6003EB Q36394208-1DBF4A03-47E0-4725-9187-4E6674889D01 Q36758670-90352D50-C360-49E8-A5B3-B548B5623DB0 Q36805635-37397D6F-53FA-48A3-9D17-408F186CDC9F Q36936179-2675990C-D2E0-44D0-89A9-68CC3F4D290C Q36936249-3D27F663-61DE-4957-882C-B9A48C5909AA Q36937355-7EE3255D-1EF7-4BD8-8FB8-6DCCFD729F40 Q37252855-683190D3-7439-43CC-8834-0157F028C89E Q37482137-66B5552E-F9D7-4F1D-A086-CF334EE4C457 Q37482204-9B436623-0872-4FE5-B640-EDFED83982AE Q37591538-B452D1C2-6228-4209-A208-E625154F0337 Q37702193-B3951432-B119-476A-8290-E9EB4EDF2106 Q37706929-1BE95E8B-1C86-4000-BA34-86C014111580 Q38601706-2C2595E7-3E60-42F5-9146-450E55F84F96 Q38622052-5078957A-EAAD-4F6B-9158-1795F88B28F3

P2860

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

http://www.wikidata.org/entity/Q34506441

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

@ast

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

@en

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

@nl

type

label

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

@ast

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

@en

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

@nl

prefLabel

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

@ast

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

@en

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

@nl

P1433

Q34506441-3FC63FB9-7BB9-4E17-B7B2-BF5D1EBC5771

P1476

Q34506441-18B725BE-83A1-421B-BA64-3AAA2227902C

P2093

Q34506441-0DD4571A-07E3-4794-958C-7D029D81049C

Q34506441-67F0F9E5-9EEF-4773-A608-D5F341E890B5

Q34506441-98184B30-D014-427B-8B26-45F33E6F40D4

Q34506441-DCA3FCA6-17D5-459E-9438-E418B6C33B23

Q34506441-DEEE573B-778D-4E1B-8D5F-2D592DF5EB21

Q34506441-EE663F73-AB8D-4448-BA1D-0B02FB8D8ECC

P2860

Q34506441-0C23CE48-7843-4B99-B502-2BE18821EDF6

Q34506441-10768CF8-E7AA-43AD-9DD5-3A3A0F471615

Q34506441-14DA89B9-1B5A-4FA8-A54D-51A0E83FDA72

Q34506441-1F9CD20C-CB22-4168-BA07-D2959F88B025

Q34506441-204CEADB-D8A0-455E-8BDB-99E4B8287231

Q34506441-2194F634-2292-4B65-AB10-CB08154A0EA2

Q34506441-23F7E2A2-D0EF-4D1B-893A-CE5DADB3697E

Q34506441-26CFAFE6-3CC7-42AF-8CED-BB1E2823AF54

Q34506441-33D33E83-CCA2-4DBE-B686-483A796DB942

Q34506441-3578A40E-B758-45ED-977F-0B386297E71E

P2888

Q34506441-75AD535E-1D22-4F29-AE44-2F5C2DAD8CA4

P304

Q34506441-DED7605C-4FF5-4A03-BC52-FAEEAB4E6707

P31

Q34506441-7385B517-DEE5-4CAD-944B-41253CAA1E9E

P356

Q34506441-2B6074C5-E07A-407A-96C6-0958B738BAD2

P407

Q34506441-A390E7B0-535E-4867-B636-8040F30F2691

P433

Q34506441-165EE70E-C4F5-4E6A-BEC1-7F75BE94A745

P478

Q34506441-0C97382C-8728-438C-AC86-67FC159A5509

P50

Q34506441-0B5C976C-1CB8-4C3B-AA9F-107412E2CC57

Q34506441-DC7AE04B-BCF9-4871-B10F-307D3A5C3FC8

P577

Q34506441-A1D5E583-1918-42E8-987F-B02BB3098B9B

P6179

Q34506441-D7BEC21B-A208-48EE-9A10-573017A90326

P698

Q34506441-F554A689-09A5-49DC-AA02-A06A465AED39

P932

Q34506441-C741CDF3-9481-444D-9F46-C0AFF6179419

P356

P1433

P1476

Insulator dysfunction and oncogene activation in IDH mutant gliomas.

@en

P2093

Anat O Stemmer-Rachamimov

http://www.w3.org/2001/XMLSchema#string

Andrew S Venteicher

http://www.w3.org/2001/XMLSchema#string

Bradley E Bernstein

http://www.w3.org/2001/XMLSchema#string

Brian B Liau

http://www.w3.org/2001/XMLSchema#string

Mario L Suvà

http://www.w3.org/2001/XMLSchema#string

William A Flavahan

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Widespread plasticity in CTCF occupancy linked to DNA methylation

Multiplex genome engineering using CRISPR/Cas systems

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

A decade of exploring the cancer epigenome - biological and translational implications

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

An integrated genomic analysis of human glioblastoma multiforme

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Comprehensive mapping of long-range interactions reveals folding principles of the human genome

P2888

P304

110-114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE16490

http://www.w3.org/2001/XMLSchema#string

P407

P433

7584

http://www.w3.org/2001/XMLSchema#string

P478

529

http://www.w3.org/2001/XMLSchema#string

P50

Shawn M. Gillespie

P577

2015-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1017311368

http://www.w3.org/2001/XMLSchema#string

P698

26700815

http://www.w3.org/2001/XMLSchema#string

P932

4831574

http://www.w3.org/2001/XMLSchema#string